Literature DB >> 20085846

Active search for chronic thromboembolic pulmonary hypertension does not appear indicated after acute pulmonary embolism.

Sulaiman Surie1, Nadine S Gibson, Victor E A Gerdes, Berto J Bouma, Berthe L F van Eck-Smit, Harry R Buller, Paul Bresser.   

Abstract

INTRODUCTION: Chronic thromboembolic pulmonary hypertension (CTEPH) is a life threatening but often, by pulmonary endarterectomy, curable disease. The incidence of CTEPH after an acute pulmonary embolism (PE) appears to be much higher than previously thought. Systematic follow-up of patients after PE might increase the number of diagnosed CTEPH patients. AIM: To study whether, compared to current clinical practice, a systematic search for CTEPH in patients after acute PE would increase the number of patients diagnosed with symptomatic, potentially treatable CTEPH.
METHODS: Consecutive patients with a prior diagnosis of acute PE were presented with a questionnaire, designed to establish the presence of either new or worsened dyspnea after the acute PE episode. If so, patients were evaluated for the presence of CTEPH.
RESULTS: PE patients (n=110; 56+/-18 years) were included after a median follow-up of three years. Overall mortality was 34% (37 patients); 1 patient had died due to CTEPH. In total 62 out of 69 questionnaires were returned; 23 patients reported new or worsened dyspnea related to the PE episode, and qualified for additional testing. In 2 patients, CTEPH was already diagnosed prior to this study. None of the remaining patients met the criteria for the diagnosis of CTEPH. The overall incidence of 2.7% (3/110; 95%CI 0.6-7.8%) is in agreement with earlier reported incidences.
CONCLUSION: Our findings do not point to a role for a systematic search and pro-active approach towards patients with a recent history of pulmonary embolism to increase the number of patients diagnosed with potentially treatable CTEPH. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20085846     DOI: 10.1016/j.thromres.2009.12.016

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  18 in total

Review 1.  Chronic thromboembolic pulmonary hypertension.

Authors:  Karen M Olsson; Bernhard Meyer; Jan Hinrichs; Jens Vogel-Claussen; Marius M Hoeper; Serghei Cebotari
Journal:  Dtsch Arztebl Int       Date:  2014-12-12       Impact factor: 5.594

Review 2.  Right ventricle in acute and chronic pulmonary embolism (2013 Grover Conference series).

Authors:  Christian Gerges; Nika Skoro-Sajer; Irene M Lang
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

Review 3.  How I use catheter-directed interventional therapy to treat patients with venous thromboembolism.

Authors:  Suresh Vedantham; Akhilesh K Sista
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

4.  Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism.

Authors:  Ming Sheng Lim; Dee Nandurkar; Ian Jong; Anita Cummins; Huyen Tran; Sanjeev Chunilal
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

5.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

6.  Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism.

Authors:  Nicolas Coquoz; Daniel Weilenmann; Daiana Stolz; Vladimir Popov; Andrea Azzola; Jean-Marc Fellrath; Hans Stricker; Alberto Pagnamenta; Sebastian Ott; Silvia Ulrich; Sandor Györik; Jérôme Pasquier; John-David Aubert
Journal:  Eur Respir J       Date:  2018-04-04       Impact factor: 16.671

Review 7.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 8.  Coagulation and the vessel wall in pulmonary embolism.

Authors:  Sherin Alias; Irene M Lang
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

Review 9.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

10.  Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.

Authors:  Sulaiman Surie; Herre J Reesink; J Tim Marcus; Mart N van der Plas; Jaap J Kloek; Anton Vonk-Noordegraaf; Paul Bresser
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.